After investing in their Series B, Lilly bags a license for a batch of metabolic candidates
Eli Lilly will license in Regor Therapeutics therapies for metabolic disorders, as a part of an agreement announced Friday that will give the Chinese biotech an upfront payment of up to $50 million, part of which is an equity investment.
In a vaguely worded release, Lilly said it has a license for certain Regor “intellectual property” and will have an option to extend that license. In exchange, Lilly will oversee global clinical development and commercialization for any therapies, with the exception of China, Macau, Hong Kong and Taiwan. Regor, a Shanghai-based company, will reserve the rights to these regions.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
